Related Experiment Video

Updated: Jul 19, 2026

A Modified Inflammatory Pain Model to Study the Analgesic Effect in Mice
06:54

A Modified Inflammatory Pain Model to Study the Analgesic Effect in Mice

Published on: November 15, 2024

An estrogen receptor-beta agonist is active in models of inflammatory and chemical-induced pain

Liza Leventhal1, Michael R Brandt, Terri A Cummons

  • 1Neuroscience Discovery Research, Wyeth Research, Princeton, NJ 08543, United States.

European Journal of Pharmacology
|October 24, 2006
PubMed

Insights

ERB-041, a selective estrogen receptor-beta agonist, shows promise in reducing pain sensitivity in preclinical models of inflammation. This suggests potential for managing inflammatory pain conditions.

Area of Science:

  • Pharmacology
  • Pain Research
  • Endocrinology

Background:

  • Estrogen receptor-beta (ERB) plays a role in various physiological processes.
  • ERB-041 is a selective ERB agonist investigated for rheumatoid arthritis and endometriosis.
  • The impact of ERB-beta on inflammatory pain is not well understood.

Purpose of the Study:

  • To investigate the effect of ERB-041 on pain modulation in preclinical models.
  • To determine if ERB-041 exhibits anti-hyperalgesic properties in inflammatory pain conditions.

Main Methods:

  • Utilized preclinical models of chemical-induced and acute inflammatory pain.
  • Administered ERB-041 to assess its impact on pain responses.

Main Results:

  • Acutely administered ERB-041 demonstrated anti-hyperalgesic effects.
  • ERB-041 reduced pain sensitivity in the tested inflammatory pain models.

Conclusions:

  • ERB-041 possesses anti-hyperalgesic properties in preclinical models of inflammatory pain.
  • ERB-041 may be a potential therapeutic agent for modulating pain associated with certain inflammatory conditions.

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...